In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations
- PMID: 37665985
- DOI: 10.7326/J23-0063
In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations
Abstract
Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.
Conflict of interest statement
Comment on
-
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical